MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtcme.2026.06.002

Медицинская библиотека · Journal of traditional and complementary medicine · 2026

Astragalus membranaceus therapy in patients with spinocerebellar ataxia type 3.

Chiu Chungmin, Cheng Wenling, Lin Tatsung, Chang Huiju, Tseng Minhui, Chang Yujun, Su Shihli, Lee Chiaju, Chang Henhong, Liu Chinsan

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIM: Spinocerebellar ataxia type 3 (SCA3) is the most common form of hereditary cerebellar ataxia. The insulin/insulin-like growth factor 1 (IGF1) system (IIS) has been proposed as a potential target for disease-modifying therapy. Astragalus membranaceus (AM) may modulate the IIS pathway and reduce neurodegeneration, as indicated by plasma neurofilament light chain (NfL), a biomarker of disease progression.

EXPERIMENTAL PROCEDURE: A randomized, triple-blind, placebo-controlled crossover trial was conducted in 32 patients with SCA3. Participants received AM or placebo for three months, followed by a one-month washout, then crossed over to the alternate treatment. Plasma NfL and IIS-related markers were measured. Twenty-three participants completed the trial.

RESULTS AND

CONCLUSION

Intention-to-treat analysis revealed a modest within-treatment reduction in NfL levels (27.6 ± 10.7 vs. 25.6 ± 9.8 pg/mL, P = 0.040) and increased insulin (12.5 ± 15.2 vs. 21.1 ± 15.5 μIU/mL, P = 0.004) after AM. However, the adjusted regression model showed no significant between-treatment difference in NfL (P = 0.127), and changes in NfL were not correlated with insulin. No significant changes were observed in IGF1 or IGF-binding proteins. Exploratory subgroup analyses suggested larger biomarker changes in later-stage patients. No carryover effects or demographic differences were noted. Overall, AM administration was associated with modest within-treatment biomarker changes in NfL and insulin, although the adjusted between-treatment difference in NfL was not statistically significant. These findings should be interpreted cautiously as preliminary and hypothesis-generating observations rather than confirmatory evidence of therapeutic efficacy.

Для цитирования: Chiu Chungmin, Cheng Wenling, Lin Tatsung, Chang Huiju, Tseng Minhui, Chang Yujun, Su Shihli, Lee Chiaju, Chang Henhong, Liu Chinsan. Astragalus membranaceus therapy in patients with spinocerebellar ataxia type 3.. Journal of traditional and complementary medicine. 2026. DOI: 10.1016/j.jtcme.2026.06.002.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.